(NewsDirect)
ReShape Lifesciences CEO Paul Hickeyjoined Steve Darling from Proactive to share significant newsregarding the approval of the company's next-generation Lap-Band®2.0 FLEX by the U.S. Food and Drug Administration.
Hickey told Proactive this FDA approvalrepresents a historic event for ReShape Lifesciences and is expectedto serve as a pivotal driver of growth for the company's Lap-Bandfranchise. The development of the enhanced Lap-Band 2.0 FLEX was ledby physicians with a primary focus on improving the overall patientexperience.
This FDA approval marks a significant milestonefor ReShape Lifesciences, highlighting the company's commitment toadvancing patient-centered innovations in the field of medicaldevices.
Contact Details
Proactive USA
+1347-449-0879
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.